Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2016
At a glance
- Drugs JNJ 61187191 (Primary) ; JNJ 61187165
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Crucell Holland
- 31 Oct 2016 Status changed from recruiting to completed.
- 07 Oct 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 01 Oct 2015 New trial record